Pirtobrutinib Patent Expiration
Pirtobrutinib is Used for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy including a BTK inhibitor and a BCL-2 inhibitor. It was first introduced by Loxo Oncology Inc
Pirtobrutinib Patents
Given below is the list of patents protecting Pirtobrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jaypirca | US12109193 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | Sep 14, 2041 | Loxo Oncol |
| Jaypirca | US10342780 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
| Jaypirca | US10464905 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
| Jaypirca | US10695323 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
| Jaypirca | US10918622 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
Pirtobrutinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List